Ascentage Pharma Group International 6-K Filing
Ticker: AAPG · Form: 6-K · Filed: Apr 1, 2026 · CIK: 0002023311
Sentiment: neutral
Filing Stats: 196 words · 1 min read · ~1 pages · Grade level 14 · Accepted 2026-04-01 16:30:25
Filing Documents
- ea0284650-6k_ascentage.htm (6-K) — 11KB
- ea028465001ex99-1.htm (EX-99.1) — 6KB
- ea028465001_ex99-1img1.jpg (GRAPHIC) — 18KB
- 0001213900-26-038557.txt ( ) — 43KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2026 Commission File Number: 001-42484 ASCENTAGE PHARMA GROUP INTERNATIONAL (Translation of Registrant’s name into English) 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F On April 1, 2026, Ascentage Pharma Group International (“Ascentage Pharma” or the “Company”) issued an announcement entitled, “Change of Principal Place of Business in Hong Kong”. A copy of the announcement is furnished as Exhibit 99.1 to this Report. 1 INDEX TO EXHIBITS Exhibit Number Exhibit Title 99.1 Announcement dated April 1, 2026 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ASCENTAGE PHARMA GROUP INTERNATIONAL Date: April 1, 2026 /s/ Dajun Yang Name: Dajun Yang Title: Chief Executive Officer 3